Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · Real-Time Price · USD
3.850
+0.350 (10.00%)
At close: Dec 5, 2025, 4:00 PM EST
3.999
+0.149 (3.88%)
After-hours: Dec 5, 2025, 7:58 PM EST
Gain Therapeutics Stock Forecast
Stock Price Forecast
According to 6 professional analysts, the 12-month price target for Gain Therapeutics stock ranges from a low of $6.00 to a high of $12. The average analyst price target of $8.00 forecasts a 107.79% increase in the stock price over the next year.
Price Target: $8.00 (+107.79%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Oct 15, 2025.
Analyst Ratings
The average analyst rating for Gain Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 5 | 5 | 5 |
| Buy | 2 | 2 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +133.77% | Oct 15, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +107.79% | Oct 13, 2025 |
| Maxim Group | Maxim Group | Strong Buy Maintains $5 → $7 | Strong Buy | Maintains | $5 → $7 | +81.82% | Oct 7, 2025 |
| BTIG | BTIG | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +133.77% | Sep 8, 2025 |
| Roth Capital | Roth Capital | Strong Buy Maintains $7 → $6 | Strong Buy | Maintains | $7 → $6 | +55.84% | Aug 13, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.66
from -0.89
EPS Next Year
-0.78
from -0.66
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | -0.66 | -0.65 | ||
| Avg | -0.66 | -0.78 | ||
| Low | -0.65 | -0.93 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | - | - | ||
| Avg | - | - | ||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.